Virginia M-Y Lee

Professor

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (10)

Epigenetic mechanisms, including histone acetylation, regulate learning and memory and underlie Alzheimer’s disease and related dementia (ADRD). Acetyl-CoA synthetase 2 (ACSS2), an enzyme generating acetyl-CoA, locally regulates histone acetylation and gene expression in neuronal nuclei. This regulatory mechanism may be a promising target for therapeutic intervention in neurodegenerative diseases. Previously, we showed that systemic ACSS2 knockout mice, although largely normal in physiology, exhibit memory deficits. Here, we investigated whether increasing ACSS2 levels could protect neurons against disease and age-associated cognitive decline. Given the role of tau in ADRD, we used primary hippocampal neurons that mimic the sporadic development of tau pathology and the P301S transgenic mouse model for tau-induced memory decline. Our results show that ACSS2 upregulation mitigates tau-induced transcriptional alterations, enhances neuronal resilience against tau pathology, improves long-term potentiation, and ameliorates memory deficits. Additionally, boosting histone acetylation through ACSS2 countered age-related memory decline. These findings indicate that increasing ACSS2 is highly effective in countering age- and tau-induced transcriptome changes, preserving elevated levels of synaptic genes, and safeguarding synaptic integrity. These findings position ACSS2 as a key epigenetic regulator of cognitive aging and ADRD, highlighting its potential for targeted therapeutics to enhance brain resilience and function.

Year:

2026

Neuronal hyperexcitability is a hallmark of amyotrophic lateral sclerosis (ALS), but its relationship with the TDP-43 aggregates that comprise the predominant pathology in over 90% of ALS cases remains unclear. Emerging evidence indicates that TDP-43 pathology induces neuronal hyperexcitability, which may contribute to excitotoxic neuronal death. To characterize TDP-43 mediated network excitability changes in a disease-relevant model, we performed in vivo continuous electroencephalography monitoring and ex vivo acute hippocampal slice electrophysiology in rNLS8 mice (males and females), which express human TDP-43 with a defective nuclear localization signal (hTDP-43ΔNLS). Surprisingly, we identified the presence of seizures in ∼64% of rNLS8 mice beginning ∼2.5 weeks after transgene induction (off-DOX). More broadly, we observed longitudinal changes in cortical EEG patterns and circuit hyperexcitability preceding neurodegeneration of vulnerable hippocampal subfields. Consistent with previous reports, we have observed broad dysregulation of AMPA subunit expression in mice expressing hTDP-43ΔNLS. These changes were most pronounced in the hippocampus, where we hypothesized they promote hyperexcitability and ultimately, excitotoxic cell death. Interestingly, hippocampal injection of AAV encoding inhibitory DREADDs (hM4Di) and daily activation with CNO ligand rescued anxiety deficits on the elevated zero maze but did not reduce neurodegeneration. Moreover, therapeutic doses of the antiseizure medications, valproic acid and levetiracetam, did not improve behavior or prevent neurodegeneration. These results highlight the complex relationship between TDP-43-mediated neuronal hyperexcitability and neurodegeneration. Although targeting hyperexcitability may ameliorate some behavioral deficits, our study suggests it may not be sufficient to halt or slow neurodegeneration in TDP-43-related proteinopathies.

Year:

2025

Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE , as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.

Year:

2025

Structurally diverse tau filaments form proteinaceous aggregates in a heterogeneous group of neurodegenerative diseases called tauopathies 1 . The factors extrinsic to the highly ordered core structure that influence tau filament stability are not well understood. Here, we found that polyubiquitinated tau filaments from Alzheimer’s disease and vacuolar tauopathy human brain tissue exhibit distinct seeding patterns in mice, in association with differences in tau filament ultrastructure determined by cryo-electron microscopy. Interestingly, chemical modulation of the polarity of polyubiquitin adjacent to the tau core with the small molecule ubistatin B resulted in the repositioning of poorly structured densities towards positively charged residues on the highly structured core filament, leading to shifting of the protofilament-protofilament interface of certain vacuolar tauopathy tau filaments. These results suggest that the structure of tau filaments that are associated with different seeding activities in vivo can be influenced by post-translational modifications.

Year:

2025

Year:

2024

The transmission of tau pathology has been proposed as one of the major mechanisms for the spatiotemporal spreading of tau pathology in neurodegenerative diseases. Over the last decade, studies have demonstrated that targeting total or pathological tau using tau antibodies can mitigate the development of tau pathology in tauopathy or Alzheimer's disease (AD) mouse models, and multiple tau immunotherapy agents have progressed to clinical trials. Tau antibodies are believed to inhibit the internalization of pathologic seeds and/or block seed elongation after seed internalization. To further address the mechanism of tau antibody inhibition of pathological spread, we conducted immunotherapy studies in mouse primary neurons and wild-type mice (females) seeded with AD patient-derived tau to induce the formation and spreading of tau pathology. Notably, we evaluated the effect of a mouse tau-specific antibody (mTau8) which does not interact with AD–tau seeds in these models. Our results show that mTau8 crosses the blood–brain barrier at levels similar to other antibodies and effectively decreases AD–tau-seeded tau pathology in vitro and in vivo. Importantly, our data suggest that mTau8 binds to endogenous intraneuronal mouse tau, thereby inhibiting the elongation of internalized tau seeds. These findings provide valuable insights into the possible mechanism underlying antibody-based therapies for treating tauopathies.

Year:

2024

Aggregation of misfolded alpha-synuclein (aSyn) within the brain is the pathologic hallmark of Lewy body diseases (LBD), including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Evidence exists for aSyn “strains” – conformations with distinct biological properties. However, biomarkers for PD vs. DLB, including potential aSyn strain differences, are lacking. Here, we used two monoclonal antibodies selective for different in vitro aSyn species – termed Strain A and B – to evaluate human brain tissue, cerebrospinal fluid (CSF), and plasma. Surprisingly, levels of Strain A and B aSyn species differed in plasma from individuals with PD vs. DLB in two independent cohorts. Lower plasma aSyn Strain A species also predicted subsequent PD cognitive decline. Strain A and Strain B aSyn species were undetectable in CSF, but plasma aSyn species could template aSyn fibrillization, particularly in PD. Our findings suggest that aSyn strains may impact LBD clinical presentation and originate outside the brain.

Year:

2024

To elucidate the molecular basis of multiple system atrophy (MSA), a neurodegenerative disease, we conducted a genome-wide association study (GWAS) in a Japanese MSA case/control series followed by replication studies in Japanese, Korean, Chinese, European, and North American samples. In the GWAS stage, rs2303744 on chromosome 19 showed a suggestive association ( P = 6.5 × 10 − 7 ) that was replicated in additional Japanese samples ( P = 2.9 × 10 − 6 , odds ratio (OR) = 1.58; 95% confidence interval (CI), 1.30–1.91), and then confirmed as highly significant in a meta-analysis of East Asian population data ( P = 5.0 × 10 − 15 , OR = 1.49; 95% CI 1.35–1.65). The association of rs2303744 with MSA remained significant in combined European/North American samples ( P = 0.017, OR = 1.12; 95% CI 1.02–1.23) despite allele frequencies being quite different between these populations. rs2303744 leads to an amino acid substitution in PLA2G4C that encodes the cPLA2γ lysophospholipase/transacylase. The cPLA2γ-Ile143 isoform encoded by the MSA risk allele has significantly decreased transacylase activity compared with the alternate cPLA2γ-Val143 isoform, and may perturb membrane phospholipids and promote oligodendroglial pathology.

Year:

2024

Year:

2023

Year:

2023

Collaborators (67)

Alice S. Chen‐Plotkin

Sponsor

University of Pennsylvania

UNITED STATES
View details

Stefanie Heilmann-Heimbach

Head of Laboratory, Research Group Leader

University Hospital Bonn

GERMANY
View details

Maria Jesús Bullido Gómez-Heras

Researcher

Universidad Autónoma de Madrid

SPAIN
View details

Pau Pastor

Institut Català de la Salut

SPAIN
View details

Eloy Rodriguez-Rodríguez

Instituto de Investigación Marqués de Valdecilla

SPAIN
View details

Edward B Lee

PI

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Henrik Zetterberg

Professor

University of Gothenburg

SWEDEN
View details

Shelley L. Berger

Director

University of Pennsylvania

UNITED STATES
View details

Agustín Ruiz Laza

Director of the Biology Core

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Harro Seelaar

Neurologist

Erasmus MC

NETHERLANDS
View details

Sonja Scholz

National Institute of Neurological Disorders and Stroke

UNITED STATES
View details

Johannes Kornhuber

-

GERMANY
View details

Thomas F. Tropea

-

UNITED STATES
View details

Henne Holstege

Professor

KU Leuven

BELGIUM
View details

Markus Nöthen

Professor, Director

University Hospital Bonn

GERMANY
View details

Suzanne Schindler

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Pieter Jelle Visser

Karolinska Institutet

SWEDEN
View details

Jordi Pérez-Tur

Coordinador Adjunto al Área Global Vida

Agencia Estatal Consejo Superior de Investigaciones Científicas

SPAIN
View details

Ken Yamamoto

Professor

Kurume University

JAPAN
View details

Jean-Charles Lambert

Head of research unit

INSERM

FRANCE
View details

Kelvin Luk

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Betty Tijms

Senior researcher

VU medisch centrum

NETHERLANDS
View details

Simon Laws

Professor

Edith Cowan University

AUSTRALIA
View details

Henry Houlden

Professor of Neurogenetics

-

UNITED KINGDOM
View details

David Irwin

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Jonathan Vogelgsang

Harvard University

UNITED STATES
View details

Ciyang Wang

Washington University in St. Louis

UNITED STATES
View details

Daniel Weintraub

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Timothy Hohman

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Pablo Mir

-

SPAIN
View details

Tatiana Foroud

Department Chair

Indiana University

UNITED STATES
View details

Norbert Scherbaum

Professor for Clinical Addiction Research

University of Duisburg-Essen Faculty of Medizin

GERMANY
View details

Ullrich Wüllner

University of Bonn

GERMANY
View details

Margda Waern

University of Gothenburg

SWEDEN
View details

Nancy M. Bonini

PI

University of Pennsylvania

UNITED STATES
View details

Osamu Onodera

Professor

Niigata University

JAPAN
View details

Muhammad Ali

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Tatsushi Toda

University of Tokyo

JAPAN
View details

Andrew Saykin

Professor and Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center

Indiana University School of Medicine

UNITED STATES
View details

Sami Heikkinen

Research Director

University of Eastern Finland

FINLAND
View details

Wiesje van der Flier

Scientific director

VU medisch centrum

NETHERLANDS
View details

John Dani

Chair, Director, Professor

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

David M. Holtzman

Washington University School of Medicine

UNITED STATES
View details

Dan Rujescu

Head of Clinical Division of General Psychiatry

Medical University of Vienna

AUSTRIA
View details

Yi-Wei Chang

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Robert Perneczky

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Gen Sobue

Nagoya University

JAPAN
View details

Martin Ingelsson

Specialist

Uppsala University Hospital

SWEDEN
View details

Hilkka Soininen

Kuopio University Hospital

FINLAND
View details

Shoji Tsuji

Professor

International University of Health and Welfare

JAPAN
View details

George Burslem

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Norihito Uemura

Senior Lecturer

Kyoto University

JAPAN
View details

Emil Gustavsson

Assistant Research Professor

University of Cambridge

UNITED KINGDOM
View details

Riccardo E Marioni

University of Edinburgh

UNITED KINGDOM
View details

Alison Goate

Professor and Chair

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Alfredo Ramirez

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Masato Koike

Professor and Chairman

Juntendo University Graduate School of Medicine

JAPAN
View details

Shinichi Morishita

Project Professor

University of Tokyo

JAPAN
View details

Carlos Cruchaga

Professor

Washington University in St. Louis

UNITED STATES
View details

Ville Leinonen

Professor

University of Eastern Finland

FINLAND
View details

Lutz Froelich

Head

Zentralinstitut für Seelische Gesundheit

GERMANY
View details

Rebecca Sims

Senior Research Fellow

Cardiff University

UNITED KINGDOM
View details

Lars Bertram

Professor of Genome Analytics

University of Lübeck

GERMANY
View details

Cornelia Van Duijn

Professor

University of Oxford

UNITED KINGDOM
View details

Alberto Lleó

Director

Hospital de la Santa Creu i Sant Pau

SPAIN
View details

Sterling Johnson

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Menghan Liu

Washington University in St. Louis

UNITED STATES
View details